RTP Mobile Logo
Questions from the Community: Investigators Provide Perspectives on Challenging Clinical Issues in the Management of Non-Small Cell Lung Cancer
Released October 2015

Audio proceedings of a live educational activity held adjunct to the 2015 ASCO Annual Meeting on controversial issues in the management of lung cancer featuring the perspectives of Drs Corey J Langer, Tony SK Mok, Lecia V Sequist, David R Spigel and Heather Wakelee. (Audio Content)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    OVERVIEW OF ACTIVITY
    Lung cancer is a devastating disease with a broad-reaching effect on public health, accounting for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. Development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge. The advent of these next-generation targeted treatments presents new promise of both efficacy and enhanced safety for patients with lung cancer but also challenges practicing oncologists to appropriately select individuals who may benefit from these agents and to determine how to integrate such therapies, as they become available, into standard lung cancer treatment algorithms. Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making lung cancer management decisions in the face of this dynamic clinical environment, but despite the existence of these tools, many areas of controversy persist within academic and community settings. This program uses a review of recent relevant publications and other relevant presentations, ongoing clinical trials, actual patient case discussions and Q&A to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies, including referral of appropriate patients to ongoing pivotal clinical trials.

    LEARNING OBJECTIVES

    • Develop an evidence-based strategy for the diagnosis and management of localized NSCLC, including the use of adjuvant systemic therapy.
    • Apply the results of emerging clinical research to optimize the multimodality management of Stage III NSCLC.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
    • Devise an evidence-based approach to the selection of induction and maintenance systemic therapy for patients with NSCLC without a targetable mutation.
    • Assess available research evidence with existing and emerging therapeutic options for patients with advanced squamous cell carcinoma of the lung, and use this information to guide clinical care and protocol opportunities for these individuals.
    • Consider published safety and efficacy data with available and emerging therapeutic strategies to appropriately incorporate them into the management of EGFR mutation-positive NSCLC.
    • Describe emerging data on the efficacy and safety of tumor immunotherapy, including approaches directed at the PD-1/PD-L1 pathways in lung cancer, and consider this information when counseling patients regarding protocol and nonprotocol treatment options.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in NSCLC, and counsel appropriately selected patients about study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Spigel has no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LangerAdvisory Committee: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clarient Inc, Clovis Oncology, Genentech BioOncology, Lilly, Merck, Myriad Genetic Laboratories Inc, Roche Laboratories Inc; Consulting Agreements: Abbott Laboratories, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Merck, Pfizer Inc, Takeda Oncology, Veridex LLC; Data Safety Monitoring Committee: Amgen Inc, Synta Pharmaceuticals Corp. Dr MokAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc. Dr SequistConsulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Taiho Oncology Inc. Dr WakeleeConsulting Agreement: Peregrine Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Xcovery.

    CONSULTING ONCOLOGISTSDrs Deutsch, Ferris, Glynn, Lobins and Lowenthal have no real or apparent conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2015
    Expiration date: October 2016

    This was an independent, accredited educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Questions from the Community: Investigators Provide Perspectives on Challenging Clinical Issues in the Management of Non-Small Cell Lung Cancer
Released October 2015

Audio proceedings of a live educational activity held adjunct to the 2015 ASCO Annual Meeting on controversial issues in the management of lung cancer featuring the perspectives of Drs Corey J Langer, Tony SK Mok, Lecia V Sequist, David R Spigel and Heather Wakelee. (Audio Content)

Read print: